Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. (Q37831402)

From Wikidata

Jump to navigation Jump to search

scientific article published on April 2011

Language	Label	Description	Also known as
English	Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.	scientific article published on April 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21255254 AND SRC:MED&resulttype=core&format=json

20 January 2020

0 references

1 reference

Europe PubMed Central

Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21255254 AND SRC:MED&resulttype=core&format=json

20 January 2020

0 references

0 references

0 references

venous thromboembolism

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

multiple myeloma

1 reference

based on heuristic

inferred from title

Grégoire Le Gal

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21255254 AND SRC:MED&resulttype=core&format=json

20 January 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21255254 AND SRC:MED&resulttype=core&format=json

20 January 2020

author name string

M Carrier

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21255254 AND SRC:MED&resulttype=core&format=json

20 January 2020

C Wu

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21255254 AND SRC:MED&resulttype=core&format=json

20 January 2020

A Y Lee

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21255254 AND SRC:MED&resulttype=core&format=json

20 January 2020

publication date

1 April 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21255254 AND SRC:MED&resulttype=core&format=json

20 January 2020

Journal of Thrombosis and Haemostasis

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21255254 AND SRC:MED&resulttype=core&format=json

20 January 2020

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21255254 AND SRC:MED&resulttype=core&format=json

20 January 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21255254 AND SRC:MED&resulttype=core&format=json

20 January 2020

653-663

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21255254 AND SRC:MED&resulttype=core&format=json

20 January 2020

Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism.

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Thalidomide for treatment of multiple myeloma: 10 years later

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone.

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Quantifying heterogeneity in a meta-analysis

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Deep venous thrombosis and thalidomide therapy for multiple myeloma

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Thalidomide and hematopoietic-cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism.

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Thalidomide and dexamethasone combination for refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Thromboembolic events during treatment with thalidomide

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Thalidomide and dexamethasone for resistant multiple myeloma

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Early response predicts thalidomide efficiency in patients with advanced multiple myeloma

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study.

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Combination therapy with thalidomide, incadronate, and dexamethasone for relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Low dose Velcade, thalidomide and dexamethasone (LD-VTD): an effective regimen for relapsed and refractory multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

A new standard of care for elderly patients with myeloma

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21.

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4 Foxp3 T cells.

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek myeloma study group

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04215.X

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37831402&oldid=1522566616"